INVESTMENTS – RELATED PARTIES (Tables)
|
12 Months Ended |
Dec. 31, 2025 |
|---|
| SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties [Abstract] |
|
| Schedule of investment |
| Schedule of investment | |
| |
| |
| | | |
| | |
| | |
Interest | |
| |
December 31, | | |
December 31, | |
| | |
Rate | |
Due Date | |
2025 | | |
2024 | |
| Promissory note and accrued interest receivable, Ault & Company | |
8% | |
December 31, 2024 | |
$ | - | | |
$ | 2,468,000 | |
| Promissory notes and accrued interest receivable, Gresham | |
6% - 15% | |
In bankruptcy as of December 31, 2024 | |
| - | | |
| 18,499,000 | |
| Other | |
| |
| |
| - | | |
| 335,000 | |
| Allowance for credit losses | |
| |
| |
| - | | |
| (500,000 | ) |
| Total investment in promissory notes and other, related parties | |
| |
| |
$ | - | | |
$ | 20,802,000 | |
|
| Schedule of Interest income, related party |
| Schedule of Interest income, related party | |
| | |
| |
| | |
For the Year Ended | |
| | |
December 31, | |
| | |
2025 | | |
2024 | |
| Interest income, related party | |
$ | 1,787,000 | | |
$ | 1,694,000 | |
|
| Schedule of investment in common stock |
| Schedule of investment in common stock | |
| | | |
| | | |
| | |
| | |
Investments in common stock, related parties at December 31, 2025 | |
| | |
Cost | | |
Gross unrealized losses | | |
Fair value | |
| Common shares | |
$ | 24,331,000 | | |
$ | (24,316,000 | ) | |
$ | 15,000 | |
| | |
Investments in common stock, related parties at December 31, 2024 | |
| | |
Cost | | |
Gross unrealized losses | | |
Fair value | |
| Common shares | |
$ | 24,697,000 | | |
$ | (24,607,000 | ) | |
$ | 90,000 | |
| Alzamend series B convertible preferred stock, warrants | |
| 2,100,000 | | |
| - | | |
| 2,100,000 | |
| | |
$ | 26,797,000 | | |
$ | (24,607,000 | ) | |
$ | 2,190,000 | |
|
| Schedule of investment in warrants and common stock |
| Schedule of investment in warrants and common stock | |
| | | |
| | |
| | |
For the Year Ended December 31, | |
| | |
2025 | | |
2024 | |
| Balance at January 1 | |
$ | 90,000 | | |
$ | 679,000 | |
| Investment in common stock of Alzamend | |
| 8,000 | | |
| 9,000 | |
| Sale of common stock of Alzamend | |
| (2,219,000 | ) | |
| - | |
| Conversion of invest in equity securities to marketable securities, related party | |
| 2,100,000 | | |
| - | |
| Realized loss in common stock of Alzamend | |
| (255,000 | ) | |
| - | |
| Unrealized loss in common stock of Alzamend | |
| 291,000 | | |
| (598,000 | ) |
| Balance at December 31 | |
$ | 15,000 | | |
$ | 90,000 | |
|